相关实验视频

Updated: Jul 11, 2025

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

小分子抑制剂针对调节性T细胞进行癌症治疗

Nuria García-Díaz^1,2, Qian Wei¹, Kjetil Taskén^1,2

¹Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

European journal of immunology

|November 8, 2023

概括

调节性T细胞 (Tregs) 控制免疫平衡,但通过抑制抗瘤免疫力来帮助瘤生长. 小分子抑制剂提供了一个有希望的策略来调节Tregs,以改善癌症免疫治疗.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

调节性T细胞 (Tregs) 维持免疫平衡,但通过抑制瘤微环境 (TME) 中的抗瘤免疫反应来促进瘤进展.
在TME中的Treg透与癌症患者的不良预后相关,突出了它们在瘤发育中的关键作用.
向Tregs是增强癌症免疫疗法的关键策略.

研究的目的:

提供小分子抑制剂的概述,用于调节癌症中的调节性T细胞 (Tregs).
讨论小分子抑制剂对针对Tregs的抗体治疗的优势.
强调表型试验对于特征化针对Tregs的小分子化合物的重要性.

主要方法:

对针对调节性T细胞 (Tregs) 的小分子抑制剂的文献综述.
在瘤微环境 (TME) 中分析Treg功能和招募机制.
讨论基于抗体的与小分子抑制剂的策略.

主要成果:

小分子抑制剂在临床前癌症模型中表现出调节调控性T细胞 (Treg) 活性的有效性.
小分子提供了诸如口服生物可用性和能够准TME内的细胞内蛋白质等优势.
现型分析对于评估这些抑制剂的疗效和表征这些抑制剂的作用机制至关重要.

结论:

小分子抑制剂代表了在癌症免疫治疗中向调节性T细胞 (Tregs) 的有前途的治疗方法.
需要进一步研究和开发表型分析,以优化基于小分子的Treg调制策略.
用小分子向Tregs可以增强抗瘤免疫反应并改善癌症患者的治疗结果.

关键词:

癌症癌症癌症癌症免疫治疗是一种免疫疗法.监管性T细胞监管性T细胞小分子是小分子.

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...